

## New Zealand Data Sheet

---

### 1 PRODUCT NAME

---

IBUPROFEN SR BNM 800 mg modified release tablets

---

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

---

Each modified release tablet contains 800 mg of ibuprofen.

For the full list of excipients, see section 6.1.

---

### 3 PHARMACEUTICAL FORM

---

White to off white, pillow shaped film coated tablets plain on both sides.

---

### 4 CLINICAL PARTICULARS

---

#### 4.1 Therapeutic indications

- Rheumatoid arthritis
- Osteoarthritis
- Juvenile rheumatoid arthritis
- Primary dysmenorrhoea
- Pyrexia

Ibuprofen SR BNM is also indicated for the relief of acute and/or chronic pain states in which there is an inflammatory component.

#### 4.2 Dose and method of administration

After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest duration should be used.

##### **Dose**

##### *Adult*

The recommended daily dosage is two Ibuprofen SR BNM tablets taken as a single dose, preferably in the early evening, well before retiring to bed. The tablets should be swallowed whole with plenty of fluids.

In severe or acute conditions, the total daily dosage may be increased to three tablets taken as two tablets in the early evening and an additional tablet in the morning.

#### *Maintenance dose*

In all indications the dose should be adjusted for each patient and the smallest dose that results in acceptable control of the symptoms employed. In general, patients with rheumatoid arthritis and osteoarthritis tend to require higher doses than patients with other conditions.

#### Special populations

##### *Elderly*

In elderly patients receiving 600 - 1,200 mg daily ibuprofen appeared to be well tolerated. However, since elderly patients may have a degree of impaired liver or renal function the adult dosage should be used with caution.

##### *Hepatic impairment*

Ibuprofen should be used with caution in patients with impaired liver function (see section 4.4).

##### *Renal impairment*

Ibuprofen should be used with caution in patients with impaired renal function (see section 4.4).

##### Paediatric population

Ibuprofen SR BNM is not recommended for children under 12 years.

#### **Method of administration**

The dose may be taken on an empty stomach. It is recommended that patients with sensitive stomachs take ibuprofen with food.

Take Ibuprofen SR tablets with plenty of fluid. Ibuprofen SR tablets should be swallowed whole and not chewed, broken, crushed or sucked on, to avoid oral discomfort and throat irritation.

#### **4.3 Contraindications**

- Known hypersensitivity to ibuprofen or any of the inactive ingredients (see section 6.1).
- Hypersensitivity (e.g. asthma, rhinitis or urticaria) to aspirin or other nonsteroidal anti-inflammatory drugs (NSAID).
- History of gastrointestinal bleeding or perforation, related to previous NSAID therapy.
- Active or history of ulcerative colitis, Crohn's disease, recurrent peptic ulceration or gastrointestinal haemorrhage (defined as two or more distinct episodes of proven ulceration or bleeding).
- Severe heart failure (NYHA IV).
- Severe liver failure.
- Severe renal failure (glomerular filtration below 30 mL/min).

- Conditions involving an increased tendency to or active bleeding.
- During the third trimester of pregnancy.

#### **4.4 Special warnings and precautions for use**

##### **General precautions**

Prolonged use of any painkillers may induce headaches, which must not be treated with increased doses of the painkillers, including ibuprofen.

Through concomitant consumption of alcohol, NSAID-related undesirable effects, particularly those that concern the gastrointestinal tract or the central nervous system, may be increased on use of NSAIDs.

##### **Cardiovascular thrombotic events**

Ibuprofen should be given with care to patients with a history of heart failure or hypertension since edema has been reported in association with ibuprofen administration.

Clinical studies suggest that use of ibuprofen, particularly at a high dose (2,400 mg/day) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen ( $\leq 1,200$  mg/day) is associated with an increased risk of arterial thrombotic events.

Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2,400 mg/day) should be avoided.

Careful consideration should also be exercised before initiating treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2,400 mg/day) are required.

There is no consistent evidence that the concurrent use of aspirin mitigates the possible increased risk of serious cardiovascular thrombotic events associated with NSAID use.

Cases of Kounis syndrome have been reported in patients treated with Ibuprofen SR BNM. Kounis syndrome has been defined as cardiovascular symptoms secondary to an allergic or hypersensitive reaction associated with constriction of coronary arteries and potentially leading to myocardial infarction.

##### **Hypertension**

NSAIDs may lead to onset of new hypertension or worsening of pre-existing hypertension and patients taking antihypertensives with NSAIDs may have an impaired anti-hypertensive response.

Caution is advised when prescribing NSAIDs to patients with hypertension. Blood pressure should be monitored closely during initiation of NSAID treatment and at regular intervals thereafter.

**Heart failure**

Fluid retention and oedema have been reported in association with ibuprofen, therefore, the medicine should be used with caution in patients with a history of heart failure or hypertension.

**Gastrointestinal events**

Ibuprofen should be used with extreme caution, and at the lowest effective dose, in patients with a history of gastrointestinal haemorrhage or ulcer since their condition may be exacerbated.

All NSAIDs can cause gastrointestinal discomfort and serious, potentially fatal gastrointestinal effects such as ulcers, bleeding and perforation which may increase with dose or duration of use, but can occur at any time without warning. Upper GI ulcers, gross bleeding or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short term therapy is not without risk.

Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, as well as patients requiring concomitant low dose aspirin, or for other drugs likely to increase gastrointestinal risk (see section 4.5).

The concomitant administration of ibuprofen and other NSAIDs, including cyclooxygenase-2 (Cox-2) selective inhibitors, should be avoided due to the increased risk of ulceration or bleeding (see section 4.5).

Caution is advised in patients with risk factors for gastrointestinal events who may be at greater risk of developing serious gastrointestinal events, e.g. the elderly, those with a history of serious gastrointestinal events, smoking and alcoholism.

Caution should be exercised in patients receiving concomitant medication which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin re-uptake inhibitors or antiplatelet drugs such as aspirin (see section 4.5).

The concurrent use of aspirin and NSAIDs also increases the risk of serious gastrointestinal adverse events.

When gastrointestinal bleeding or ulcerations occur in patients receiving NSAIDs, the drug should be withdrawn immediately. Doctors should warn patients about signs and symptoms of serious gastrointestinal toxicity.

**Severe cutaneous adverse reactions (SCARs)**

Severe cutaneous adverse reactions (SCARs), including exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with the use of ibuprofen (see section 4.8). Most of these reactions occurred within the first month of treatment. . If signs and symptoms suggestive

of these reactions appear ibuprofen should be withdrawn immediately and an alternative treatment considered (as appropriate).

In exceptional cases, varicella can be at the origin of serious cutaneous and soft tissue infectious complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of ibuprofen in case of varicella.

### **Infections and infestations**

Exacerbation of skin infection-related inflammations (e.g. development of necrotising fasciitis) coinciding with the use of NSAIDs has been described. If signs of an infection occur or get worse during use of ibuprofen the patient is therefore recommended to consult a doctor without delay.

### **Respiratory disorders**

Caution is required if ibuprofen is administered to patients suffering from, or with a previous history of bronchial asthma, chronic rhinitis or allergic diseases since ibuprofen has been reported to cause bronchospasm, urticarial or angioedema in such patients.

### **Ophthalmological effects**

Adverse ophthalmological effects have been observed with NSAIDs; accordingly, patients who develop visual disturbances during treatment with ibuprofen should have an ophthalmological examination.

### **Impaired liver function or a history of liver disease**

Patients with impaired liver function or a history of liver disease who are on long term ibuprofen therapy should have hepatic function monitored at regular intervals. Ibuprofen has been reported to have a minor and transient effect on liver enzymes.

Severe hepatic reactions, including jaundice and cases of fatal hepatitis, though rare, have been reported with ibuprofen as with other NSAIDs. If abnormal liver tests persist or worsen, or if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), ibuprofen should be discontinued.

### **Impaired renal function**

Caution should be used when initiating treatment with ibuprofen in patients with considerable dehydration. There is a risk of renal impairment especially in dehydrated elderly children and adolescents.

The two major metabolites of ibuprofen are excreted mainly in the urine and impairment of renal function may result in their accumulation. The significance of this is unknown. NSAIDs have been reported to cause nephrotoxicity in various forms; interstitial nephritis, nephrotic syndrome and renal failure. In patients with renal, cardiac or hepatic impairment, those taking diuretics and ACE inhibitors, and the elderly, caution is required since the use of NSAIDs may result in deterioration of renal function.

The long term concomitant intake of various analgesics further increases the risk. For patients with renal, hepatic or cardiac impairment, use the lowest effective dose, for the

shortest possible duration and monitor renal function especially in long term treated patients.

#### **Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics**

The use of an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist), an anti-inflammatory drug (NSAID or COX-2 inhibitor) and thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed-combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment.

#### **Aseptic meningitis**

Aseptic meningitis has been reported only rarely, usually but not always in patients with systemic lupus erythematosus (SLE) or other connective tissue disorders.

#### **Haematological monitoring**

Blood dyscrasias have been rarely reported. Patients on long term therapy with ibuprofen should have regular haematological monitoring.

#### **Coagulation defects**

Like other NSAIDs, ibuprofen can inhibit platelet aggregation. Ibuprofen has been shown to prolong bleeding time (but within the normal range) in normal subjects. Because this prolonged bleeding effect may be exaggerated in patients with underlying haemostatic defects, ibuprofen should be used with caution in persons with intrinsic coagulation defects and those on anticoagulation therapy.

#### **Masking signs of infection**

As with other drugs of this class, ibuprofen may mask the usual signs of infection.

#### **Withdrawal of concomitant steroid therapy**

In order to avoid exacerbation of disease or adrenal insufficiency, patients who have been on prolonged corticosteroid therapy should have their therapy tapered slowly rather than discontinued abruptly when ibuprofen is added to the treatment program.

#### **Elderly population**

Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.

### **4.5 Interaction with other medicines and other forms of interaction**

#### Anticoagulants

Care should be taken in patients treated with anticoagulants, such as warfarin, due to an enhanced effect of anticoagulants.

Concurrent use of NSAIDs and warfarin has been associated with severe sometimes fatal haemorrhage. The mechanism of this interaction is not known but may involve increased

bleeding from NSAID-induced gastrointestinal ulceration or an additive effect of NSAID inhibition of platelet function with the anticoagulant effect of warfarin.

Ibuprofen SR BNM should only be used in patients taking warfarin if absolutely necessary. Patients taking this combination must be closely monitored.

Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs)

Increased risk of gastrointestinal bleeding.

Aminoglycosides

NSAIDs may decrease the excretion of aminoglycosides.

Lithium

Ibuprofen has been shown to decrease the renal clearance and increase plasma concentrations of lithium.

Lithium plasma concentrations should be monitored in patients on concurrent ibuprofen therapy.

Cardiac glycosides

NSAIDs may exacerbate cardiac failure, reduce glomerular filtration rate and increase plasma cardiac glycoside levels. Care should therefore be taken in patients treated with cardiac glycosides.

Cholestyramine

The concomitant administration of ibuprofen and cholestyramine may reduce the absorption of ibuprofen in the gastrointestinal tract. However, the clinical significance is unknown.

Corticosteroids

Increased risk of gastrointestinal ulceration or bleeding.

Herbal extracts

Ginkgo biloba may potentiate the risk of bleeding with NSAIDs.

Other analgesics

Avoid concomitant use of two or more NSAIDs, including aspirin and cyclooxygenase-2 (COX-2) selective inhibitors, because of the potential of increased adverse effects. Ibuprofen antagonizes the irreversible inhibition of platelet COX-1 induced by low dose aspirin. To reduce this effect, ibuprofen should be administered at least 8 hours before or 30 minutes after taking low dose aspirin.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. Refer to section 5.1 for information on pharmacodynamic studies.

Ciclosporin or tacrolimus

Increased risk of nephrotoxicity when used with NSAIDs.

#### Methotrexate

NSAIDs inhibit tubular secretion of methotrexate in animals. As a result, reduction of clearance of methotrexate may occur. Use of high doses of methotrexate concomitant with NSAIDs should be avoided. At low doses of methotrexate caution should be used if ibuprofen is administered concomitantly.

#### Mifepristone

A decrease in the efficacy of the medicinal product can theoretically occur due to the antiprostaglandin properties of NSAIDs including acetylsalicylic acid. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of medicinal termination of pregnancy.

#### Quinolone antibiotics

Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.

#### Sulfonylureas

NSAIDs may potentiate the effects of sulfonylurea medications. There have been rare reports of hypoglycaemia in patients on sulfonylurea medications receiving ibuprofen.

#### Zidovudine

Increased risk of haematological toxicity when NSAIDs are given with zidovudine. There is evidence of an increased risk of hemarthroses and hematoma in HIV(+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen.

#### Others

Ibuprofen like other NSAIDs can reduce the antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonists and beta-blockers with possible loss of blood pressure control and can attenuate the natriuretic effects of diuretics. Diuretics can also increase the risk of nephrotoxicity of NSAIDs. The combined use of the three classes of drugs, diuretics, an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist) and an anti-inflammatory drug (NSAID or COX-2 inhibitor) all at the same time increases the risk of renal impairment (see section 4.4).

#### CYP2C9 inhibitors

Concomitant administration of ibuprofen with CYP2C9 inhibitors may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitors), an increased S(+)-ibuprofen exposure by approximately 80 to 100% has been shown. Reduction of the ibuprofen dose should be considered when potent CYP2C9 inhibitors are administered concomitantly, particularly when high-dose ibuprofen is administered with either voriconazole or fluconazole.



#### **4.6 Fertility, pregnancy and lactation**

##### **Pregnancy**

(Category C)

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and congenital malformation including but not limited to cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy.

In animals, the administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation losses and embryo/foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.

During the first and second trimester of pregnancy, ibuprofen should not be given unless the expected benefits to the mother outweigh the risks to the fetus. If ibuprofen is used by a woman attempting to conceive, or during the first or second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the second or third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to renal dysfunction, which may progress to renal failure with oligohydramnios and, in some cases, neonatal renal impairment. Oligohydramnios is generally seen after days to weeks of treatment, although it has been reported as soon as 48 hours after ibuprofen initiation. Oligohydramnios is usually, but not always, reversible after treatment discontinuation. Consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours. Discontinue treatment with Ibuprofen SR BNM tablets if oligohydramnios occurs.

NSAID use during the 3rd trimester, may expose the mother and the neonate to the following:

- Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension).
- fetal renal impairment
- Possible prolongation of bleeding time by inhibition of platelet aggregation.
- Inhibition of uterine contractions, which may result in delayed or prolonged labour and birth.

Consequently, ibuprofen is contraindicated during the third trimester of pregnancy.

##### Use in labour and delivery

Administration of ibuprofen is not recommended during labour and delivery. The onset of labour may be delayed and the duration increased with a greater bleeding tendency in both mother and child.

### **Breastfeeding**

In the limited studies so far available, ibuprofen appears in the breast milk in very low concentrations. Ibuprofen is not recommended for use in nursing mothers.

### **Fertility**

The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of ibuprofen should be considered.

#### **4.7 Effects on ability to drive and use machines**

Following treatment with ibuprofen, the reaction time of patients may be affected. Care should be taken when driving or operating machinery as the activity may be affected by dizziness, drowsiness, fatigue and visual disturbance. This applies to a greater extent in combination with alcohol.

#### **4.8 Undesirable effects**

The pattern of adverse events reported for ibuprofen is similar to that for other NSAIDs.

##### **Gastrointestinal**

The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis and gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease (see section 4.3) have been reported following ibuprofen administration. Less frequently, gastritis, duodenal ulcer and gastric ulcer and gastrointestinal perforation have been observed.

##### **Immune system disorders**

Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, very rarely, erythema multiforme, bullous dermatoses (including Stevens-Johnson syndrome, toxic epidermal necrolysis).

##### **Skin and subcutaneous tissue disorders**

In exceptional cases, severe skin infections and soft-tissue complications may occur during a varicella infection (see section 4.4).

##### **Cardiac and vascular disorders**

Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400mg/ day) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).

The following adverse reactions possibly related to ibuprofen are displayed by MedDRA frequency convention and system organ classification. Frequency groupings are classified according to the subsequent conventions: very common ( $\geq 1/10$ ), Common ( $\geq 1/100$  to

<1/10), Uncommon ( $\geq 1/1,000$  to  $<1/100$ ), Rare ( $\geq 1/10,000$  to  $<1/1,000$ ), Very rare ( $<1/10,000$ ) and Not known (cannot be estimated from the available data).

System organ class	Frequency	Adverse reaction
Infections and infestations	Uncommon	Rhinitis.
	Rare	Aseptic meningitis (see section 4.4).
Blood and lymphatic system disorders	Rare	Thrombocytopenia, leucopenia, neutropenia, agranulocytosis, aplastic anaemia and haemolytic anaemia.
Immune system disorders	Uncommon	Hypersensitivity.
	Rare	Anaphylactic reaction.
Psychiatric disorders	Uncommon	Insomnia, anxiety.
	Rare	Depression, confusional state.
Nervous system disorders	Common	Headache, dizziness.
	Uncommon	Paraesthesia, somnolence.
	Rare	Optic neuritis.
	Not known	Hallucinations, malaise, and drowsiness.
Eye disorders	Uncommon	Visual impairment, visual disturbances.
	Rare	Toxic optic neuropathy.
Ear and labyrinth disorders	Uncommon	Hearing impaired, tinnitus, vertigo.
Respiratory, thoracic and mediastinal disorders	Uncommon	Asthma, bronchospasm, dyspnoea.
Gastrointestinal disorders	Common	Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, hematemesis, gastrointestinal haemorrhage.
	Uncommon	Gastritis, duodenal ulcer, gastric ulcer, mouth ulceration, gastrointestinal perforation.
	Very rare	Pancreatitis.
	Not known	Exacerbation of colitis and Crohn's disease.
Hepatobiliary disorders	Uncommon	Hepatitis, jaundice, abnormal liver function.
	Very rare	Hepatic failure.
	Common	Rash.

Skin and subcutaneous tissue disorders	Uncommon	Urticaria, pruritus, purpura, angioedema, photosensitivity reaction.
	Very rare	Severe cutaneous adverse reactions (SCARs) (including Erythema multiforme, exfoliative dermatitis, bullous reactions including Stevens-Johnson syndrome, and toxic epidermal necrolysis)
	Not known	DRESS syndrome (Drug reaction with eosinophilia and systemic symptoms)  AGEP (Acute Generalized Exanthematous Pustulosis)
Renal and urinary disorders	Uncommon	Renal nephrotoxicity in various forms, including tubulointerstitial nephritis, nephrotic syndrome and renal failure.
Pregnancy, puerperium and perinatal conditions	Not known	Oligohydramnios, neonatal renal impairment.
General disorders and administration site conditions	Common	Fatigue.
	Rare	Oedema.
	Not known	Decreased appetite
Cardiac disorders	Very rare	Cardiac failure, myocardial infarction (see section 4.4).
	Not known	Stroke, Kounis syndrome
Vascular disorders	Very rare	Hypertension.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions : <https://pophealth.my.site.com/carmreportnz/s/>

## 4.9 Overdose

### Toxicity

Signs and symptoms of toxicity have generally not been observed at doses below 100 mg/kg in children or adults. However, supportive care may be needed in some cases. Children have been observed to manifest signs and symptoms of toxicity after ingestion of 400 mg/kg or greater.

### Symptoms

Most patients who have ingested significant amounts of ibuprofen will manifest symptoms within 4 to 6 hours. The most frequently reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, convulsion and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnoea and depression of the CNS and respiratory system have also been rarely reported. Cardiovascular toxicity, including hypotension, bradycardia and tachycardia, has been reported. In cases of significant overdose, renal failure and liver damage are possible. Large overdoses are generally well tolerated when no other drugs are being taken.

### Treatment

There is no specific antidote for ibuprofen overdose. Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially toxic amount, activated charcoal should be considered. If necessary, serum electrolyte balance should be corrected.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

---

## **5 PHARMACOLOGICAL PROPERTIES**

---

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Anti-inflammatory and Antirheumatic Products, Non-Steroids. ATC code: M01AE01.

Ibuprofen is a racemic mixture of [+]S- and [-]R-enantiomers.

#### **Pharmacodynamic effects**

Ibuprofen is a propionic acid derivative nonsteroidal NSAID with analgesic, anti-inflammatory and anti-pyretic effects. The drug's therapeutic effects are thought to result from its inhibitory effect on the enzyme cyclooxygenase, which results in a marked reduction in prostaglandin synthesis. These properties provide symptomatic relief of inflammation, pain and fever.

#### **Clinical efficacy and safety**

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. Some pharmacodynamic studies show that when single doses of ibuprofen 400 mg were taken within 8 hours before or within 30 minutes after immediate release aspirin dosing (81 mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long term use of ibuprofen may

reduce the cardioprotective effect of low-dose acetylsalicylic acid/aspirin cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).

## **5.2 Pharmacokinetic properties**

### **Absorption**

Ibuprofen 800 mg modified release tablets provide a gradual release of the active substance, with a slower release compared to immediate release formulations and a lower peak serum concentration which is reached about 3 hours after administration. The sustained absorption phase that results provides prolonged plasma levels of ibuprofen in the systemic circulation, as a result, ibuprofen 800 mg modified release tablets only need to be taken once daily.

The pharmacokinetic profile of two sustained release 800 mg tablets compared to one immediate release 400 mg tablet taken four times daily, showed that the modified release formulation reduced the difference between the peaks and troughs characteristic of the immediate release tablets and produced higher mean plasma levels at 5, 10 and 15 hours and 24 hours. Compared with immediate-release tablets, the area under the plasma concentration/time curve (AUC) for two modified release tablets was similar.

### **Distribution**

Ibuprofen is extensively bound to plasma proteins (99%). Ibuprofen has a small volume of distribution being about 0.12-0.2 L/kg in adults.

### **Biotransformation**

Ibuprofen is rapidly metabolized in the liver through cytochrome P450, preferentially CYP2C9, to two primary inactive metabolites, 2-hydroxyibuprofen and 3-carboxyibuprofen. Following oral ingestion of the drug, slightly less than 90% of an oral dose of ibuprofen can be accounted for in the urine as oxidative metabolites and their glucuronic conjugates. Very little ibuprofen is excreted unchanged in the urine.

### **Elimination**

Excretion by the kidney is both rapid and complete. The elimination half-life of immediate release formulations is approximately two hours. The excretion of ibuprofen is virtually complete 24 hours after the last dose.

### **Special populations**

#### ***Elderly***

Given that no renal impairment exists, there are only small, clinically insignificant differences in the pharmacokinetic profile and urinary excretion between the young and the elderly.

#### ***Renal impairment***

For patients with mild renal impairment, increased plasma level of (S)-ibuprofen, higher AUC values for (S)-ibuprofen and increased enantiomeric AUC (S/R) ratios as compared

with healthy controls have been reported. In end-stage renal disease patients receiving dialysis, the mean free fraction of ibuprofen was about 3% compared with about 1% in healthy volunteers. Severe impairment of renal function may result in accumulation of ibuprofen metabolites. The significance of this effect is unknown. The metabolites can be removed by haemodialysis (see sections 4.2, 4.3 and 4.4).

#### Hepatic impairment

Alcoholic liver disease with mild to moderate hepatic impairment did not result in substantially altered pharmacokinetic parameters.

In cirrhotic patients with moderate hepatic impairment (Child Pugh's score 6-10) treated with racemic ibuprofen, an average 2-fold prolongation of the half-life was observed and the enantiomeric AUC ratio (S/R) was significantly lower compared to healthy controls suggesting an impairment of metabolic inversion of (R)-ibuprofen to the active (S)-enantiomer (see sections 4.2, 4.3 and 4.4).

### **5.3 Preclinical safety data**

Refer to sections 4.5 and 4.6 for relevant data.

---

## **6 PHARMACEUTICAL PARTICULARS**

---

### **6.1 List of excipients**

Xanthan gum  
Hypromellose  
Povidone  
Colloidal anhydrous silica  
Stearic acid  
Purified talc  
Titanium dioxide

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

3 years.

### **6.4 Special precautions for storage**

Store below 25°C.

**6.5 Nature and contents of container**

Ibuprofen SR BNM modified release tablets are presented in PVC/PVdC/Aluminium blisters packed in a carton. Pack size 30 tablets.

Ibuprofen SR BNM modified release tablets are presented in HDPE bottles. Pack size 160 tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Any unused medicine or waste material should be disposed of in accordance with local requirements.

---

**7 MEDICINE SCHEDULE**

---

Prescription Medicine

---

**8 SPONSOR**

---

BNM Group  
39 Anzac Road  
Browns Bay  
Auckland 0753

Phone 0800 565 633

---

**9 DATE OF FIRST APPROVAL**

---

01 August 2019

---

**10 DATE OF REVISION OF TEXT**

---

24 May 2024



Summary table of changes

<b>Section Changed</b>	<b>Summary of New Information</b>
4.4	Addition of Kounis syndrome under Cardiovascular thrombotic events and update information for Severe cutaneous adverse reactions (SCARs)
4.8	Addition of adverse reaction Kounis syndrome under cardiac disorders and updated adverse reactions for Skin and subcutaneous tissue disorders